D. Schliephake

A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects

N. Czeloth, B. Lang, Willem Hettema, 2017, Expert opinion on investigational drugs.

Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study.

S. Opal, T. Welte, R. Dellinger, 2015, Respiratory medicine.

Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study)

E. Rabe, F. Pannier, D. Schliephake, 2010, Phlebology.

Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.

E. Rabe, F. Pannier, D. Schliephake, 2008, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

Efficacy and safety of Aethoxysklerol® (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study)

Z. Jing, D. Schliephake, G. Malouf, 2012, Phlebology.

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC

Edward S. Kim, B. Liedert, K. Rohr, 2021, JTO clinical and research reports.

The French Polidocanol Study on Long‐Term Side Effects: A Survey Covering 3,357 Patient Years

F. Allaert, D. Schliephake, J. Guex, 2010, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

Blimp‐1 overcomes the block in IgM secretion in lipopolysaccharide / anti‐μ F(ab′)2‐co‐stimulated B lymphocytes

D. Schliephake, A. Schimpl, D. Schliephake, 1996, European journal of immunology.